Webinar
National ALS Registry: Learn How You Can Join the Fight Against ALS.
VirtualNational ALS Registry: Learn How You Can Join the Fight Against ALS.
ALS & Relationships, Sex, and Intimacy
VirtualAbout the Program A person living with ALS may not feel comfortable addressing relationship, intimacy and sexual health changes that occur during their ALS journey with their healthcare providers. Although […]
Clinical Trial Recruitment & Retention: A Path Forward
VirtualALS clinical trials must represent all people living with ALS including those from diverse genetic, racial/ethnic, socioeconomic, and geographical backgrounds.
In March 2022, I AM ALS hosted the inaugural I AM ALS Action Summit to engage stakeholders in the ALS community to improve the clinical trial experience for people living with ALS and their caregivers. Summit participants included people living with ALS, loved ones and caregivers, physicians, clinical research coordinators, advocacy organizations, biopharma allies, and key government stakeholders.
This webinar, which will take place on March 8th at 6pm ET, aims to inform the ALS community of the results from the Action Summit and will include an exchange of ideas around clinical trial recruitment and retention and ways in which you can get involved.
American Brain Coalition’s educational series: Regulatory 101
Federal agencies provide an important forum for the brain community to connect with policymakers and officials, including in support of efforts to deliver safe and effective treatments for brain conditions. […]
Weekly HEALEY ALS Platform Trial Webinar
VirtualPlease join us on Thursday, March 16th at 5:00 pm EST (4:00 pm CST/2:00 pm PST) for a webinar about the HEALEY ALS Platform Trial. Merit Cudkowicz, MD, MSc and Sabrina Paganoni, […]
Phase 2 Trial Of AP-101 In SOD1 And Sporadic ALS
VirtualIn this webinar, Dr. Angela Genge will discuss the research behind AP-10l and provide an overview of the trial and what study participation involves. The phase 2 trial of AP-101 is currently enrolling participants with Familial Amyotrophic Lateral Sclerosis and Sporadic Amyotrophic Lateral Sclerosis.